GENELUX CORPORATION Financial and Nonfinancial Liabilities, Fair Value Disclosure
GENELUX CORPORATION (GNLX) had Financial and Nonfinancial Liabilities, Fair Value Disclosure of $169.00 thousand as of 2022-12-31, per its 10-K filed 2024-03-29.
Discontinued › Notes
us-gaap:LiabilitiesFairValueDisclosure · last filed 2024-03-29
- 2022-12-31: Financial and Nonfinancial Liabilities, Fair Value Disclosure $169.00K.
| Period end | Financial and Nonfinancial Liabilities, Fair Value Disclosure |
|---|---|
| 2022-12-31 | $169.00K 10-K · filed 2024-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |